On Air Now

Listen

Listen Live Now » 100.3 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
73° Feels Like: 73°
Wind: WSW 7 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Clear 56°

Tomorrow

Isolated Thunderstorms 77°

Wed Night

Clear 57°

Alerts

Incorrect biopsy results cloud Nymox Pharma prostate cancer study

(Reuters) - Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies.

In the mid-stage study, patients receiving a single injection of the drug, NX-1207, had less cancer progression in the treated area than in untreated patients.

The main goal of the trial was to show a significantly higher number of patients with undetectable prostate cancer after 45 days of treatment, compared to untreated patients.

However, the company was unable to assess the drug's benefit because of a high percentage of false negative biopsies - a result suggesting there is no cancer present when it actually is - in the untreated patients' group.

Nymox's shares were down 3 percent at $4.98 in morning trading on the Nasdaq.

(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

Comments